Maze Therapeutics Management
Management criteria checks 1/4
Maze Therapeutics' CEO is Jason Coloma, appointed in Jul 2019, has a tenure of 5.83 years. total yearly compensation is $5.84M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $4.75M. The average tenure of the management team and the board of directors is 1.7 years and 4.6 years respectively.
Key information
Jason Coloma
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 9.04% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.7yrs |
| Board average tenure | 4.6yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$3m |
| Dec 31 2024 | US$6m | US$527k | US$3m |
Compensation vs Market: Jason's total compensation ($USD5.84M) is above average for companies of similar size in the US market ($USD2.68M).
Compensation vs Earnings: Insufficient data to compare Jason's compensation with company performance.
CEO
Jason Coloma (48 yo)
Dr. Jason V. Coloma, Ph D., M.P.H., MBA, serves as the Chief Executive Officer and Director of Maze Therapeutics, Inc. since July 2019 and served as its President, Chief Mazer and Chief Operating Officer u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$5.84m | 0.95% $ 4.8m | |
| President of Research & Development and Chief Medical Officer | 2yrs | US$2.40m | 0% $ 0 | |
| General Counsel & Corporate Secretary | less than a year | US$2.22m | 0% $ 0 | |
| Senior VP of Finance & CFO | 3.3yrs | no data | 0.030% $ 148.8k | |
| Vice President of R&D Infrastructure and Operations | no data | no data | no data | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Chief Strategy & Business Officer | 4.2yrs | no data | 0.020% $ 102.6k | |
| Senior Vice President of Technical Operations & Supply Chain | 1.3yrs | no data | no data | |
| Senior Vice President of Research | 1.3yrs | no data | no data | |
| Senior Vice President of Drug Discovery | 1.3yrs | no data | no data | |
| VP & Corporate Controller | no data | no data | no data |
Experienced Management: MAZE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$5.84m | 0.95% $ 4.8m | |
| Independent Non-Employee Director | 4.6yrs | US$118.10k | 0% $ 0 | |
| Non-Employee Chairman of the Board | 6.9yrs | US$1.12m | 0.15% $ 751.6k | |
| Independent Non-Employee Director | 5.9yrs | US$178.22k | 0.047% $ 238.1k | |
| Independent Non-Employee Director | 5.6yrs | US$98.10k | 0.047% $ 238.1k | |
| Independent Non-Employee Director | 4.3yrs | US$113.43k | 0% $ 0 | |
| Independent Non-Employee Director | less than a year | no data | no data | |
| Independent Non-Employee Director | 4.3yrs | US$113.43k | 0% $ 0 | |
| Independent Non-Employee Director | 3.1yrs | US$119.32k | 0.24% $ 1.2m |
Experienced Board: MAZE's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 02:13 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Maze Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Anupam Rama | J.P. Morgan |
| Joseph Schwartz | Leerink Partners LLC |